Aldosterone as a cardiovascular risk hormone.
The pathophysiological role of aldosterone in the development of cardiovascular disease has long been considered to be due its potent volume expansion/hypertensive effect mainly via mineralocorticoid receptor (MR) expressed in renal tubular epithelial cells. However, recent accumulating lines of evidence from clinical and experimental studies have suggested that direct cardiovascular effect of aldosterone contributes to the development of cardiovascular injury via MRs in non-epithelial tissue. A series of recent clinical studies have revealed that patients with primary aldosteronism have higher incidence of cardiovascular and renal complications than those with essential hypertension, and that aldosterone antagonism has cardiovascular protective effect in patients with heart failure independent from blood pressure. Numerous experimental studies have shown that both inflammation and oxidative stress play an initial and key role in the development of aldosterone-induced cardiovascular injury via non-epithelial MR activation. In this review, we discuss recent research progress in aldosterone and MR effects, with special emphasis on the pathophysiological role of aldosterone in cardiovascular diseases and the possible molecular mechanism(s) of cardiovascular injury by non-epithelial MR activation.
Yoshimoto
Takanobu
T
Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Japan.
Hirata
Yukio
Y
D000450:Aldosterone / Q000502:physiology*; D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology*; D004847:Epithelial Cells / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D018384:Oxidative Stress / Q000502:physiology; D018161:Receptors, Mineralocorticoid / Q000378:metabolism; D012307:Risk Factors
D018161:Receptors, Mineralocorticoid; D000804:Angiotensin II; D000450:Aldosterone